Woodland Hills Compounding Pharmacy (Algunas, Inc.), Woodland Hills, CA
Is Woodland Hills Compounding Pharmacy (Algunas, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Woodland Hills Compounding Pharmacy (Algunas, Inc.) hold a California pharmacy license?
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018358 for ALGUNAS INC, WOODLAND HILLS, CA, status NOT RENEWED, as of Nov 13, 2026.
Has Woodland Hills Compounding Pharmacy (Algunas, Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Mar 24, 2020), 1 state referral letter (Mar 25, 2020) and 1 FMD-145 letter (Mar 25, 2020) for Woodland Hills Compounding Pharmacy (Algunas, Inc.). State board actions: no California State Board of Pharmacy action under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026. The Illinois Department of Financial and Professional Regulation’s license dataset also lists “Probation” dated Jun 5, 2019, case 2018002762 on nonresident license 054018358. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Algunas, Inc.; Woodland Hills Compounding Pharmacy
- Location
- Woodland Hills, CA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Mar 25, 2020
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 4 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Algunas, Inc. (dba Woodland Hills Compounding Pharmacy), a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Mar 25, 2020 | FMD-145 letter | FMD-145 Letter Issued 03/25/2020 | Not linked by FDA |
| Mar 25, 2020 | State referral letter | State Referral Letter Issued 03/25/2020 | Not linked by FDA |
| Mar 24, 2020 | Warning letter close-out | Warning Letter Closeout Issued 03/24/2020 | Not linked by FDA |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Algunas Inc., Woodland Hills, CA (FEI number 3011830726), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Oct 11, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011830726 | 1069078 |
| Apr 29, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011830726 | 971393 |
Form 483s FDA has published for this site
- Oct 11, 2018: Form 483 to Algunas Inc., published Apr 30, 2019. fda.gov
- May 19, 2016: Form 483 to Algunas Inc., published Jan 17, 2024. fda.gov
- May 19, 2016: Form 483 to Algunas Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 4 numbered observations in all, across 2 inspections ending Apr 29, 2016 to Oct 11, 2018. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Oct 4, 2018 to Oct 11, 2018: 1 observation
- Firm on the cover
- Algunas Inc., dba Woodland Hills Compounding Pharmacy, 20631 Ventura B lvd Ste 305, Woodland Hill s, CA, 91364-2352 Type of Establishment Inspect ed: Produ cer of Non-Ster ile Drugs
- FDA district office on the cover
- Not read
- Matched to this page by
- firm name, city and state on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically,
Since 2017, rather than using USP grade <Redacted B 4>, your firm has been using a < Redac ted B4> brand <R edacted B4> sys tem whi ch you do not routinel y test to a ssure its production quality and contamination risks in the preparation of the following of your non-sterile drug products:
d n
Topical Facial Pads
Clean Face Pads (Salicylic Acid 2%, Sulfacetamide 5%, Clindamycin 0.5%) Daily Facial Peel (Pads) (Glycolic Acid 1%, Salicylic Acid 1%, Lactic Acid 3%) Skin Lightening Pads (Hydroquinone 4%, Kojic Acid 4%, Lactic Acid 3%) Ultra Complexion Pads (Glycolic Acid 10%, Salicylic Acid 5%) Topical Facial Solutions
Glycolic Acid Soln Retinoic Acid Soln Thrichloroacetic Acid Soln Tranexamic Acid 4.8% Soln Topical Dental Gels and Rinse
BTT 12.5 Gel (Lidocaine 12.5%, Tetracaine 12.5%, Prilocaine 3%, Phenylephrine 3%) Chlorhexidine 2% Gel
Short Chain Fatty Acid Enema Sod Butyrare 100 mm/L Enema
Inspection Apr 25, 2016 to Apr 29, 2016: 3 observations
- Firm on the cover
- Al gunas Inc., dba Woodlan d Hills Compounding Pharmacy, 20631 Ve ntura Bl vd , Suite 305, Woodland Hills, CA 91364-2382
- FEI number
- 3011830726
- Establishment type on the cover
- Producer of Non-Sterile Drug Products
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov); FDA also posts it as https://www.fda.gov/media/98069/download
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
Specifically,
A. The firm's SOP titled "Handling Medication Events for Compounded Preparations" does not require the firm to review and maintain complaint files and adverse drug reports (ADE) for the drugs produced at this facility. For example, after receiving a complaint about the BTT 12.5% gel drug product, the firm did not document the complaint or maintain a log of their communication with the medical provider who reported the problem.
B. The firm's training SOPs do not require employees to report ADEs to the firm's management or document conversations with medical providers or patients.
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of
its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
A. The firm does not have a procedure requiring investigation into failed or rejected batches that do not meet specification. In addition, the firm does not maintain a log of failed or rejected batches and did not always conduct a root-cause analysis of the cause of the failures. Per the firm's President the firm had failed and/or rejected batches in the past two years but did not maintain records.
AMENDMENTl
Observation 3
Routine calibration of electronic equipment is not performed according to a written program designed to assure proper performance.
Specifically,
The REDACTED B4 pH meter is calibrated at the time of use, but has not been independently calibrated. This pH meter does not have automatic temperature correction and the firm does not have other controls in place to prevent temperature variations that may affect pH measurement. The pH calibrations are not recorded in a log to monitor for trend deviations. The pH REDACTED B4 standard used by the firm had expired six months prior REDACTED B4 lot REDACTED B4, expiry Oct 2015).
AM ENDMENT 1
State board of pharmacy records
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054018358 | LICENSED PHARMACY | ALGUNAS INC | WOODLAND HILLS, CA | NOT RENEWED |
- Jun 5, 2019: “Probation”, license 054018358, case 2018002762, ALGUNAS INC, WOODLAND HILLS, CA. Reason given in the record: “due to sister-state discipline in California.” Board list
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- California State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.